Recruiting PHASE1 INTERVENTIONAL 3-arm NCT07181694

A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects

A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of Single Subcutaneous Doses of BCD 057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects

Sponsor: Biocad

Conditions Healthy Adult Male

Interventions Adalimumab (BCD-057) 100 mg/mL Adalimumab (BCD-057) 50 mg/mL Adalimumab (Humira) 100 mg/mL

Updated 2 times since 2025 Last updated: Sep 30, 2025 Started: Mar 12, 2025 Primary completion: Nov 30, 2025 Completion: Nov 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy Adult Male and is currently actively recruiting participants. Biocad leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

2 versions recorded

Nov 2025 — Present [monthly]

Recruiting PHASE1
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE1

First recorded

Mar 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biocad

Data source: Biocad

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia
• Saint Petersburg, Russia